Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
14 May 2012Website:
http://www.avitamedical.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:02:15 GMTDividend
Analysts recommendations
Institutional Ownership
RCEL Latest News
AVITA Medical announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on November 7, 2024.
AVITA Medical's RECELL GO offers superior wound healing with less donor skin required, reducing scarring and infection risk. It has no direct competition. RECELL GO streamlines the skin grafting process, saving time and money. New products like PermeaDerm and Cohealyx offer additional growth opportunities. Despite the Q1 sales hiccup & high operating losses, AVITA's underlying technology still has promise. The stock should rally if the Q3 sales target is met & operating margins improve.
RECELL GO's launch increased SG&A expenses, contributing to AVITA Medical, Inc.'s higher net losses in Q2 2024. Despite lowering its 2024 revenue guidance, AVITA Medical still anticipates significant year-over-year growth of 37-41%. AVITA Medical's cash runway is approximately nine months, with $54.1 million in cash and securities available as of June 30, 2024.
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Joshua Jennings - TD Cowen Aaron Wukmir - Lake Street Capital Market Ross Osborne - Cantor Fitzgerald Lyanne Harrison - Bank of America Operator Good day and thank you for standing by. Welcome to the AVITA Medical Second Quarter Conference Call.
VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer, on August 13, 2024, at 4:00 p.m.
AVITA Medical today reported second-quarter commercial revenue of $15.1 million, reflecting growth of over 29% over the same period in the prior year.
VALENCIA, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Thursday, August 8, 2024.
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024.
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M.
VALENCIA, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for the RECELL GO™ System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient's own skin to treat thermal burn wounds and full-thickness skin defects.
- 1(current)
What type of business is AVITA Medical?
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
What sector is AVITA Medical in?
AVITA Medical is in the Healthcare sector
What industry is AVITA Medical in?
AVITA Medical is in the Medical Devices industry
What country is AVITA Medical from?
AVITA Medical is headquartered in United States
When did AVITA Medical go public?
AVITA Medical initial public offering (IPO) was on 14 May 2012
What is AVITA Medical website?
https://www.avitamedical.com
Is AVITA Medical in the S&P 500?
No, AVITA Medical is not included in the S&P 500 index
Is AVITA Medical in the NASDAQ 100?
No, AVITA Medical is not included in the NASDAQ 100 index
Is AVITA Medical in the Dow Jones?
No, AVITA Medical is not included in the Dow Jones index
When was AVITA Medical the previous earnings report?
No data
When does AVITA Medical earnings report?
The next expected earnings date for AVITA Medical is 07 November 2024